A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism

Neuropsychopharmacology

Volumn 30, Issue 3, 2005, Pages 582-589

  Hollander, Eric ^a,b   Phillips, Ann ^a,b   Chaplin, William ^a,b   Zagursky, Karen ^a,b   Novotny, Sherie ^a,b   Wasserman, Stacey ^a,b   Iyengar, Rupa ^a,b  

^a Seaver and New York Autism Center of Excellence   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Autism; Fluoxetine; OCD; Repetitive behaviors

Indexed keywords

FLUOXETINE; FLUVOXAMINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; AGITATION; ANOREXIA; ANXIETY DISORDER; ARTICLE; AUTISM; CHILD; CHILDREN YALE BROWN OBSESSIVE COMPULSION SCALE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPULSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; INSOMNIA; LOW DRUG DOSE; MALE; NERVOUSNESS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEDATION; SEROTONINERGIC SYSTEM; SIDE EFFECT; SUICIDAL BEHAVIOR; TREATMENT OUTCOME; URINE INCONTINENCE; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADOLESCENT; AUTISTIC DISORDER; CHILD; CROSS-OVER STUDIES; CUMULATIVE TRAUMA DISORDERS; FEMALE; FLUOXETINE; HUMANS; MALE; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 13944264748     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300627     Document Type: Article

References (24)

1. Chugani DC, Muzik O, Rothermel R, Behen M, Chakraborty P, Magner T et al (1997). Altered serotonin synthesis in the dentathalmocortical pathway in autistic boys. Ann Neurol 42: 666-669.
2. Cook EH, Leventhal BL (1996). The serotonin system in autism. Curr Opin Pediatr 8: 348-354.
3. DeLong GR, Ritch CR, Burch S (2002). Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 44: 652-659.
4. Fatemi SH, Realmuto GM, Khan L, Thuras P (1998). Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 28: 303-307.
5. Gaspar P, Cases O, Maroteaux L (2003). The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 4: 1002-1012.
6. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischman RL, Hill CL et al (1989). The Yale-brown obsessive compulsive scale I. Development, use, and reliability. Arch Gen Psychiatry 4: 1006-1011.
7. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL (1993). A double-blind comparison of clomiprmine, despramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50: 441-447.
8. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L et al (1995). Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 52: 289-295.
9. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology, NIMH Publication DHEW Publ No. 76-388. National Institute of Mental Health: Bethesda, MD.
10. Hedeker D, Gibbons RD (1996). MIXREG: a computer program for mixed effects regression analysis with autocorrelated errors. Comput Methods Programs Biomed 49: 229-252.
11. Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H et al (2003a). A double blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 64: 640-647.
12. Hollander E, Novotny S, Allen A, Aronowitz B, Cartwright C, DeCaria C (2000). The relationship between repetitive behaviors and growth hormone response to sumatriptan challenge in adult autistic disorder. Neuropsychopharmacology 22: 163-167.
13. Hollander E, Phillips AT, Yeh C (2003b). Targeted treatments for symptom domains in child and adolescent autism. Lancet 362: 732-734.
14. Markowitz PI (1992). Effect of fluoxetine on self-injurious behavior in the developmentally disabled: a preliminary study. J Clin Psychopharmacol 12: 27-31.
15. McDougle CJ, Kresch LE, Posey DJ (2000). Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 30: 427-435.
16. McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH (1996a). Effects of trytophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry 53: 993-1000.
17. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH (1996b). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53: 1001-1008.
18. Namerow LB, Prakash T, Bostic JQ, Prince J, Monuteaux MC (2003). Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 24: 104-108.
19. Novotny S, Hollander E, Allen A, Mosovich S, Aronowitz B, Cartwright C et al (2000). Increased growth hormone response to sumatriptan challenge in adult autistic disorders. Psychiatry Res 94: 173-177.
20. Pascual J, del Arco C, Romon T, del Olmo E, Castro E, Pazos A (1996). Autoradographic distribution of (3H) sumatriptan-binding sites in post-mortem human brain. Cephalagia 16: 317-322.
21. Ramchandani P (2004). Treatment of major depressive disorder in children and adolescents. Br Med J 328: 3-4.
22. Research Units on Pediatric Psychopharmacology Autism Network (2002). Risperidone in children with autism and serious behavioral problems. N Engl J Med 347: 314-321.
23. The Clomipramine Collaborative Study Group (1991). Clomiprmine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 48: 730-738.
24. Tollefson GD, Rampey Jr AH, Potvin JH, Jenike MA, Rush AJ, Kominguez RA et al (1994). A multicenter investigation of fixed dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 51: 559-567.